Table 3.

Factors associated with the 10-year overall survival of patients with unresectable hepatocellular carcinoma initially treated with TACE according to univariate and multivariate analyses

Characteristics	Univariate analysis crude HR (95% CI)	P	Multivariate analysis adjusted HR (95% CI)	P
Sorafenib user
No (reference)	1
Yes	0.30 (0.21-0.44)	<0.001	0.38 (0.25-0.57)	<0.001
Sex
Male (reference)	1
Female	0.77 (0.51-1.16)	0.205	-	-
Age (years)	0.99 (0.98-1.01)	0.364	-	-
Vascular invasion
No (reference)	1
Yes	1.06 (0.72-1.56)	0.787	-	-
Number of nodules
Single (reference)	1
Multiple-diffuse	2.11 (1.40-3.17)	<0.001	-	-
Extrahepatic metastasis
No (reference)	1
Yes	2.04 (1.37-3.02)	<0.001	2.01 (1.34-3.04)	0.001
Tumor size (cm)
≤5	1
>5	2.73 (1.88-3.96)	<0.001	2.51 (1.68-3.75)	<0.001
Liver cirrhosis
No (reference)	1
Yes	0.98 (0.61-1.57)	0.932	-	-
Child-pugh score
A (reference)	1	1	1	1
B	2.11 (1.47-3.02)	<0.001	1.35 (0.93-1.96)	0.117
C	7.69 (4.65-12.73)	<0.001	5.41 (3.20-9.14)	<0.001
AFP (ng/mL)
<400 (reference)	1
≥400	1.30 (0.94-1.80)	0.118	-	-
Hepatitis B surface antigen
Negative (reference)	1
Positive	1.10 (0.79-1.54)	0.579	1.60 (1.07-2.39)	0.021
Anti-hepatitis C virus
Negative (reference)	1
Positive	0.84 (0.59-1.20)	0.340	-	-
Antivirus agent use
No (reference)	1
Yes	0.41 (0.28-0.59)	<0.001	0.36 (0.23-0.56)	<0.001

HR: Hazard ratio, CI: Confidence interval, AFP: Alpha-fetoprotein levels